Technical Analysis for ATNX - Athenex, Inc.

Grade Last Price % Change Price Change
grade D 17.33 0.70% 0.12
ATNX closed up 0.7 percent on Friday, January 19, 2018, on 85 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
0 Watchers
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong N/A Up Up
See historical ATNX trend table...

Date Alert Name Type % Chg
Jan 19 MACD Bullish Centerline Cross Bullish 0.00%
Jan 19 Stochastic Reached Overbought Strength 0.00%
Jan 19 Wide Bands Range Expansion 0.00%
Jan 19 Above Upper BB Strength 0.00%
Jan 19 Overbought Stochastic Strength 0.00%
Jan 19 Up 3 Days in a Row Strength 0.00%
Jan 19 Up 4 Days in a Row Strength 0.00%
Jan 19 Up 5 Days in a Row Strength 0.00%
Jan 19 Upper Bollinger Band Touch Strength 0.00%
Jan 18 50 DMA Support Bullish 0.70%

Older signals for ATNX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Athenex, Inc. is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company's technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics. The Company offers Oraxol, an oral formulation of paclitaxel; Orateacan, an oral formulation of Irinotecan; Oradoxel, an oral formulation of Docetaxel, and an oral formulation of Topotecan for the treatment of various types of cancers. Its Src Kinase Inhibitors include KX-01 (KX2-391) and KX-02 (KX2-361) oncology drug candidates. The Company's Symptom Therapeutics include CQ-01, which is used for the treatment of burn pruritus and scars; CQ-R1, which is used for the treatment of an irradiation-induced dermatitis, and an intranasal Granisetron used for the treatment of chemotherapy-induced nausea/vomiting.
Is ATNX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 20.79
52 Week Low 11.21
Average Volume 259,054
200-Day Moving Average 0.0
50-Day Moving Average 16.6462
20-Day Moving Average 16.1795
10-Day Moving Average 16.111
Average True Range 0.6544
ADX 37.14
+DI 21.18
-DI 18.56
Chandelier Exit (Long, 3 ATRs ) 15.5368
Chandelier Exit (Short, 3 ATRs ) 17.0632
Upper Bollinger Band 17.2869
Lower Bollinger Band 15.0721
Percent B (%b) 1.02
BandWidth 13.688927
MACD Line 0.025
MACD Signal Line -0.1763
MACD Histogram 0.2013
Fundamentals Value
Market Cap 988.91 Million
Num Shares 57.1 Million
EPS -3.47
Price-to-Earnings (P/E) Ratio -4.99
Price-to-Sales 47.88
Price-to-Book 7.97
PEG Ratio 0.98
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.02
Resistance 3 (R3) 18.00 17.75 17.91
Resistance 2 (R2) 17.75 17.57 17.76 17.87
Resistance 1 (R1) 17.54 17.47 17.42 17.56 17.83
Pivot Point 17.29 17.29 17.23 17.30 17.29
Support 1 (S1) 17.08 17.11 16.96 17.10 16.83
Support 2 (S2) 16.83 17.01 16.84 16.79
Support 3 (S3) 16.62 16.83 16.76
Support 4 (S4) 16.64